产品
编 号：F751336
分子式：C18H19N9O4
分子量：425.4
分子式：C18H19N9O4
分子量：425.4
产品类型
规格
价格
是否有货
结构图
CAS No: 2339867-53-5
产品详情
生物活性：
PHD2/HDACs-IN-1 is a potent PHD2/HDACs hybrid inhibitor (IC50s of 1.15 μM, 19.75 μM, 26.60 μM and 15.98 μM for PHD2, HDAC1, HDAC2 and HDAC6, respectively). PHD2/HDACs-IN-1 is a low-toxicity renoprotective agent for research of cisplatin-induced acute kidney injury (AKI).
体内研究：
PHD2/HDACs-IN-1 (10 mg/kg/day; i.p.; 2 days) has significant renal protecting effects on alleviating pathological injuries with considerably decreased tubular injury scores.Animal Model:Male C57BL/6 mice (8 weeks; n=5) (Cisplatin-induced AKI)
Dosage:10 mg/kg/day
Administration:i.p., 2 days
Result:Showed significant renal protecting effects on alleviating pathological injuries with considerably decreased tubular injury scores.
体外研究：
PHD2/HDACs-IN-1 (compound 31c) (50 μM; 24 hours) and cisplatin co-treatment can further downregulate the MCF7 and A549 cell viability compared to the treatment of cisplatin alone.PHD2/HDACs-IN-1 (0.78-100 μM; 24 hours) has no evident inhibitions on HK-2 cell viabilities up to 100 μM dosing.PHD2/HDACs-IN-1 (50 μM; 24 hours) not only has potent protective activity against cisplatin-induced inhibition for normal renal tubule epithelial cells without observable toxicities.
PHD2/HDACs-IN-1 is a potent PHD2/HDACs hybrid inhibitor (IC50s of 1.15 μM, 19.75 μM, 26.60 μM and 15.98 μM for PHD2, HDAC1, HDAC2 and HDAC6, respectively). PHD2/HDACs-IN-1 is a low-toxicity renoprotective agent for research of cisplatin-induced acute kidney injury (AKI).
体内研究：
PHD2/HDACs-IN-1 (10 mg/kg/day; i.p.; 2 days) has significant renal protecting effects on alleviating pathological injuries with considerably decreased tubular injury scores.Animal Model:Male C57BL/6 mice (8 weeks; n=5) (Cisplatin-induced AKI)
Dosage:10 mg/kg/day
Administration:i.p., 2 days
Result:Showed significant renal protecting effects on alleviating pathological injuries with considerably decreased tubular injury scores.
体外研究：
PHD2/HDACs-IN-1 (compound 31c) (50 μM; 24 hours) and cisplatin co-treatment can further downregulate the MCF7 and A549 cell viability compared to the treatment of cisplatin alone.PHD2/HDACs-IN-1 (0.78-100 μM; 24 hours) has no evident inhibitions on HK-2 cell viabilities up to 100 μM dosing.PHD2/HDACs-IN-1 (50 μM; 24 hours) not only has potent protective activity against cisplatin-induced inhibition for normal renal tubule epithelial cells without observable toxicities.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备